Publications by authors named "Simon Rushbrook"

Claim this Profile
A
Assessing brodalumab in the treatment of primary sclerosing cholangitis (SABR-PSC pilot study): protocol for a single-arm, multicentre, pilot study.
Amera Elzubeir, Juliet High, Matthew Hammond, Lee Shepstone, Martin Pond, Simon Rushbrook

BMJ Open Gastroenterol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guidelines Development Group for the British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma.
Shahid A Khan, Simon M Rushbrook, Timothy James Kendall, Yoh Zen, Raneem Albazaz

Gut· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fine-mapping and molecular characterisation of primary sclerosing cholangitis genetic risk loci.
Elizabeth C Goode, Laura Fachal, Nikolaos Panousis, Loukas Moutsianas, Rebecca E McIntyre, Simon M Rushbrook

Nat Commun· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulation of intestinal senescence during cholestatic liver disease modulates barrier function and liver disease progression.
Mar Moreno-Gonzalez, Katherine Hampton, Paula Ruiz, Gemma Beasy, Falk Sp Nagies, Simon M Rushbrook

JHEP Rep· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma.
Simon M Rushbrook, Timothy James Kendall, Yoh Zen, Raneem Albazaz, Prakash Manoharan

Gut· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis.
Laura Martinez-Gili, Alexandros Pechlivanis, Julie A K McDonald, Sofina Begum, Jonathan Badrock, Simon Rushbrook

Gut Microbes· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulation of immune responses in primary biliary cholangitis: a transcriptomic analysis of peripheral immune cells.
Victoria Mulcahy, Evaggelia Liaskou, Jose-Ezequiel Martin, Prasanti Kotagiri, Jonathan Badrock, Simon M Rushbrook

Hepatol Commun· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
APOBEC mutagenesis is a common process in normal human small intestine.
Yichen Wang, Philip S Robinson, Tim H H Coorens, Luiza Moore, Henry Lee-Six, Simon Rushbrook

Nat Genet· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multitrait genome-wide analyses identify new susceptibility loci and candidate drugs to primary sclerosing cholangitis.
Younghun Han, Jinyoung Byun, Catherine Zhu, Ryan Sun, Julia Y Roh, Simon M Rushbrook

Nat Commun· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A protocol paper for the MOTION Study-A longitudinal study in a cohort aged 60 years and older to obtain mechanistic knowledge of the role of the gut microbiome during normal healthy ageing in order to develop strategies that will improve lifelong health and wellbeing.
Sarah Phillips, Rachel Watt, Thomas Atkinson, Shelina Rajan, Antonietta Hayhoe, Simon Rushbrook

PLoS One· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inherited MUTYH mutations cause elevated somatic mutation rates and distinctive mutational signatures in normal human cells.
Philip S Robinson, Laura E Thomas, Federico Abascal, Hyunchul Jung, Luke M R Harvey, Simon Rushbrook

Nat Commun· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study.
David E J Jones, Aaron Wetten, Ben Barron-Millar, Laura Ogle, George Mells, Simon Rushbrook

EBioMedicine· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Emerging Role of Bile Acids in the Pathogenesis of Inflammatory Bowel Disease.
John P Thomas, Dezso Modos, Simon M Rushbrook, Nick Powell, Tamas Korcsmaros

Front Immunol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis.
Ben Barron-Millar, Laura Ogle, George Mells, Steven Flack, Jonathan Badrock, Simon Rushbrook

Hepatology· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intestinal Microbiome-Macrophage Crosstalk Contributes to Cholestatic Liver Disease by Promoting Intestinal Permeability in Mice.
Anna Isaacs-Ten, Marta Echeandia, Mar Moreno-Gonzalez, Arlaine Brion, Andrew Goldson, Simon M Rushbrook

Hepatology· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
Kris V Kowdley, Raj Vuppalanchi, Cynthia Levy, Annarosa Floreani, Pietro Andreone, Simon Rushbrook

J Hepatol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply.
Elizabeth C Goode, Gideon M Hirschfield, Simon M Rushbrook

Hepatology· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Mechanistic Insight Into the Role of Gut Microbiota in the Pathogenesis of Primary Sclerosing Cholangitis.
Meha Patel, Alastair J M Watson, Simon Rushbrook

Gastroenterology· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
Michael Trauner, Aliya Gulamhusein, Bilal Hameed, Stephen Caldwell, Mitchell L Shiffman, Simon Rushbrook

Hepatology· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis.
Michael Huw Chapman, Douglas Thorburn, Gideon M Hirschfield, George G J Webster, Simon M Rushbrook

Gut· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System.
Elizabeth C Goode, Allan B Clark, George F Mells, Brijesh Srivastava, Kelly Spiess, Simon M Rushbrook

Hepatology· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Top research priorities in liver and gallbladder disorders in the UK.
Kurinchi S Gurusamy, Martine Walmsley, Brian R Davidson, Claire Frier, Barry Fuller, Simon M Rushbrook

BMJ Open· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fine-Tuning of Sirtuin 1 Expression Is Essential to Protect the Liver From Cholestatic Liver Disease.
Britt A Blokker, Monica Maijo, Marta Echeandia, Mikel Galduroz, Angela M Patterson, Simon M Rushbrook

Hepatology· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis.
Rudi Alberts, Elisabeth M G de Vries, Elizabeth C Goode, Xiaojun Jiang, Fotis Sampaziotis, Simon M Rushbrook

Gut· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
n-3 Fatty acids combined with flavan-3-ols prevent steatosis and liver injury in a murine model of NAFLD.
David Vauzour, Ildefonso Rodriguez-Ramiro, Simon Rushbrook, Ignacio R Ipharraguerre, Damon Bevan

Biochim Biophys Acta Mol Basis Dis· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis